uniconazole-P: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
uniconazole P : A (1E)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol that has S configuration at the chiral centre. It is the enantiomer of (R)-uniconazole; the fungicide and plant growth retardant uniconazole is the racemic mixture comprising (R)-uniconazole and uniconazole-P. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6436639 |
| CHEMBL ID | 261837 |
| CHEBI ID | 81785 |
| SCHEMBL ID | 19803 |
| MeSH ID | M0499212 |
| Synonym |
|---|
| uniconazole-p |
| uniconazole-p [iso] |
| s-3307d |
| (s)-s3307 |
| (e)-(+)-(s)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)-pent-1-ene-3-ol |
| uniconazole p |
| (s)-uniconazole |
| 1h-1,2,4-triazole-1-ethanol, beta-((4-chlorophenyl)methylene)-alpha-(1,1-dimethylethyl)-, (s-(e))- |
| lomica |
| 83657-17-4 |
| (1e,3s)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1h-1,2,4-triazol-1-yl)pent-1-en-3-ol |
| chebi:81785 , |
| (s)-(+)-uniconazole |
| CHEMBL261837 |
| (e,3s)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol |
| (e,3s)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)-1-penten-3-ol |
| A840627 |
| C18494 |
| 1h-1,2,4-triazole-1-ethanol, beta-((4-chlorophenyl)methylene)-alpha-(1,1-dimethylethyl)-, (alphas,betae)- |
| unii-2t880r8s46 |
| (s)-e-1-(4-chlorophenyl)-4,4-dimethyl-2-(1,2,4-triazole-1-yl)penten-3-ol |
| 2t880r8s46 , |
| 1h-1,2,4-triazole-1-ethanol, .beta.-((4-chlorophenyl)methylene)-.alpha.-(1,1-dimethylethyl)-, (s-(e))- |
| (e)-(s)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1h-1,2,4-triazol-1-yl)pent-1-en-3-ol |
| (.alpha.s,.beta.e)-.beta.-((4-chlorophenyl)methylene)-.alpha.-(1,1-dimethylethyl)-1h-1,2,4-triazole-1-ethanol |
| sumiseven p |
| 1h-1,2,4-triazole-1-ethanol, .beta.-((4-chlorophenyl)methylene)-.alpha.-(1,1-dimethylethyl)-, (.alpha.s,.beta.e)- |
| (s)-s 3307 |
| SCHEMBL19803 |
| (alphass,betae)-beta-[(4-chlorophenyl)methylene]-alpha-(1,1-dimethylethyl)-1h-1,2,4-triazole-1-ethanol |
| 1h-1,2,4-triazole-1-ethanol,b-[(4-chlorophenyl)methylene]-a-(1,1-dimethylethyl)-, (as,be)- |
| YNWVFADWVLCOPU-MAUPQMMJSA-N |
| 1h-1,2,4-triazole-1-ethanol, .beta.-[(4-chlorophenyl)methylene]-.alpha.-(1,1-dimethylethyl)-, (.beta.e)- |
| DTXSID3035002 |
| uniconazole-p 10 microg/ml in cyclohexane |
| (s,e)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1h-1,2,4-triazol-1-yl)pent-1-en-3-ol |
| Q27155601 |
| AKOS040744704 |
| Role | Description |
|---|---|
| plant growth retardant | null |
| antifungal agrochemical | Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. |
| EC 1.14.13.78 (ent-kaurene oxidase) inhibitor | An EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of ent-kaurene oxidase (E.C. 1.14.13.78). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| (1E)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol | A member of the class of triazoles that is 1,2,4-triazole which is substituted at position 1 by a 1-(p-chlorophenyl)-3-hydroxy-4,4-dimethylpent-1-en-2-yl group. |
| conazole fungicide | Any conazole antifungal agent that has been used as a fungicide. |
| triazole fungicide | Any triazole antifungal agent that has been used as a fungicide. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| abscisic acid degradation to neophaseic acid | 4 | 6 |
| abscisic acid degradation to phaseic acid | 5 | 8 |
| phaseic acid biosynthesis | 5 | 11 |
| neophaseic acid biosynthesis | 4 | 9 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Abscisic acid 8'-hydroxylase 3 | Arabidopsis thaliana (thale cress) | Kinact | 2.7000 | 2.7000 | 2.7000 | 2.7000 | AID322408 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID322408 | Inhibition of Arabidopsis thaliana recombinant ABA 8-hydroxylase | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Structure-activity relationship of uniconazole, a potent inhibitor of ABA 8'-hydroxylase, with a focus on hydrophilic functional groups and conformation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.73) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||